giles AI, a company making advanced research tools accessible to all and simplifying how scientists work with data, has announced the commercial launch of giles, its AI specialised research agent designed to support healthcare, clinical, and medical research. By extracting, analysing, summarising, and referencing information from verified medical databases and private files, giles enables rapid literature review, accelerating research processes.
Using an LLM-agnostic approach, giles optimises research intelligence for scientific text comprehension, data accuracy validation, citation tracking, and domain-specific language understanding for medical, clinical, and academic settings. giles searches trusted sources of information, including private personal documents, to create easily digestible abstracts and comparisons of relevant data. In addition, it cites and verifies results, all completed within seconds. With an accuracy rate of up to 94% and available in over 40 languages, giles is applicable to all aspects of life science and healthcare research, including drug discovery and development, where the tool is enhancing workflows by providing access to real-time insights.
Following its initial development, refinement and subsequent commercialisation of the AI agent was supported through a strategic partnership with Regulatory Scientific and Health Solutions (R-S-S), a leader in health economics and drug development, to connect researchers with open access medical databases. With ongoing support from Google UK, giles AI now has a series of high-profile collaborations with pharma companies, directly connecting researchers to medical databases.
giles is transforming the way we approach medical research literature review. Instead of spending hours researching, analysing, and organising data, users can simply ask our innovative AI agent, making healthcare research effortless. We are excited to share giles with both academics and researchers from across sector as we advance in our mission to make advanced AI research tools available to all, and look forward to seeing the scientific breakthroughs our technology facilitates.”
Rishi Wadhera, CEO, giles AI